Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

At the end of the trial, the participants who took semaglutide lost an average of about 14% of their body weight — roughly 33 pounds — compared to about 3% in the placebo group. People who ...